• Acasti Pharma – Fully funded to Phase 3 completion. Shares retain huge upside potential

    February 27, 2019 | Posted by

    By Richard Gill, CFA We have been followers of Nasdaq listed krill oil specialist Acasti Pharmaceuticals (ACST) for some time now, having last updated on the company in October last year. While the share price has shown some volatility since then, 2019 has so far been a good year for the company, with the shares […]

  • Align Research Top 10 Picks for 2019

    January 3, 2019 | Posted by

    To say that 2018 was a “trying” year is somewhat of an understatement. For many small and micro cap stocks, particularly the capital hungry ones and those where delivery by management of market expectations was non-existent or lacking, this resulted in almost decimatory declines for existing shareholders. The table below of the wipeouts suffered by […]

  • Acasti Pharma – Peer success shows investors could make a krilling

    October 4, 2018 | Posted by

    It’s been a good ride for investors in Nasdaq listed krill oil specialist Acasti Pharmaceuticals (ACST) since we published our LATEST ANALYSIS on Monday this week. Trading at 1.29 cents at the time of our article, the shares rose to a peak of 2.25 cents before settling to the current level of 1.56 cents. That […]

  • Acasti Pharmaceuticals – market begins to wake up to the explosive upside on offer should CaPre Phase 3 trials prove successful

    October 1, 2018 | Posted by

    By Richard Jennings It has been a slow burn for followers of us into Nasdaq listed Acasti Pharmaceuticals (ACST) as per our original article per HERE but we believe that the stock is now primed to move decisively ahead as the company moves up the most important stage of the pharma sector“value proving” curve – […]

  • Zak Mir interviews Richard Jennings, CEO, Align Research

    December 31, 2017 | Posted by

    Zak Mir interviews Richard Jennings, CEO, Align Research, discussing the on goings of the past year and the outlook for 2018. https://zakmir.files.wordpress.com/2017/12/align.m4a Key points discussed Addressing twitter/bulletin board “trolls” Elaboration on some of the top 10 picks for 2018 Global markets outlook Business model background  

Loading More